Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03389399 · ClinicalTrials.gov registry record
Pulmonary Physiology and Systemic Inflammatory in EO Pulmonary Events With Brigatinib Use in NSCLC and Other Diseases
A clinical trial of Non-Small Cell Lung Cancer, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- 18
- Enrollment target
- 5
- Study locations
NCT03389399 is a study of Non-Small Cell Lung Cancer that has completed, run by University of Colorado, Denver. The registered enrollment target is 18 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (97% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT03389399, a study of Non-Small Cell Lung Cancer, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- 18 participants
- Enrollment target
- 5
- Study locations
Study Summary
To estimate the incidence of Early Onset Pulmonary Events (EOPEs), defined as the proportion of participants with a peak reduction in DLCO of 20% or greater after commencing brigatinib at 90mg QD.
Conditions Studied
Study Locations (5)
Colorado
- University of Colorado Denver - Aurora
Pennsylvania
- University of Pittsburgh Cancer Institute - Pittsburgh
Tennessee
- Vanderbilt-Ingram Cancer Center - Nashville
Texas
- UT Southwestern Harold C Simmons Comprehensive Cancer Center - Dallas
Ontario
- Princess Margaret Cancer Centre - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2018-02-22 |
| Est. Completion | 2021-10-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03389399
The ClinicalTrials.gov registry entry for NCT03389399 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (97% lower). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT03389399 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Colorado, Pennsylvania, Tennessee.
Frequently Asked Questions
What is clinical trial NCT03389399 about?
NCT03389399 is a clinical study titled "Pulmonary Physiology and Systemic Inflammatory in EO Pulmonary Events With Brigatinib Use in NSCLC and Other Diseases". To estimate the incidence of Early Onset Pulmonary Events (EOPEs), defined as the proportion of participants with a peak reduction in DLCO of 20% or greater after commencing brigatinib at 90mg QD.
What is the current status of trial NCT03389399?
This trial is currently completed. The enrollment target is 18 participants. The study started on 2018-02-22. Estimated completion is 2021-10-01.
What conditions does trial NCT03389399 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
Who is sponsoring clinical trial NCT03389399?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03389399 being conducted?
This trial has 5 study locations across Colorado, Pennsylvania, Tennessee, Texas, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.